CD44 and cancer: Next, the in vitro experiments revealed that the tsRNA-GlyGCC inhibitor suppresses cell proliferation, migration, and formation of tumor spheres by modulating the protein expression of BCL2, BAX and cancer stem cells molecular markers (CD44,CD133, EphB2, LICAM, and LGR5).